BioSante Pharmaceuticals Announces $16.5 Million Private Placement of Common Stock
25 May 2007 - 11:26PM
Business Wire
BioSante Pharmaceuticals, Inc. (Amex: BPA) today announced that it
has entered into definitive agreements with institutional and other
accredited investors with respect to the private placement of
2,754,999 million shares of its common stock at a purchase price of
$6.00 per share, for expected gross proceeds of approximately $16.5
million, before payment of placement agent commissions and offering
expenses. Investors also will receive warrants to purchase 688,750
shares of common stock at an exercise price of $8.00 per share.
Rodman & Renshaw, LLC is serving as lead placement agent with
Oppenheimer & Co. Inc. serving as an additional placement agent
for the transaction. The transaction is expected to be completed
upon approval of an additional listing application by the American
Stock Exchange. "We are pleased with this private placement, and
are gratified to welcome new institutional investors to BioSante,"
said Stephen M. Simes, BioSante's president and chief executive
officer. �We limited the private placement to the amount raised to
minimize dilution to our existing stockholders, while adding to our
cash balance.� The expected net proceeds of approximately $15.6
million will be used to continue and expand BioSante�s previously
announced Phase III clinical program of LibiGel� for treatment of
female sexual dysfunction (FSD). The first of two Phase III safety
and efficacy studies was initiated in December 2006. Based on its
current cash balance and commitments, BioSante believes that with
the net proceeds from this private placement, it should be able to
maintain its current planned development activities and the
corresponding level of expenditures through the end of 2008,
although no assurance can be given that it will not need additional
cash prior to such time. The securities offered in this placement
have not been registered under the Securities Act of 1933, as
amended, or state securities laws, and cannot be offered or sold in
the United States absent registration with the Securities and
Exchange Commission (SEC) or an applicable exemption from the
registration requirements. As part of the transaction, the company
has agreed to file a registration statement with the SEC covering
the resale of the shares of common stock to be issued in the
offering, including the shares of common stock issuable upon
exercise of the warrants. This news release is neither an offer to
sell nor a solicitation of an offer to buy any of the securities
discussed herein and is being issued under Rule 135c of the
Securities Act of 1933. About BioSante Pharmaceuticals, Inc.
BioSante is developing a pipeline of hormone therapy products to
treat both men and women. These hormone therapy products are gel
formulations for transdermal administration that deliver
bio-identical estradiol and testosterone. BioSante's lead products
include Elestrin� (estradiol gel), developed through U.S. Food and
Drug Administration (FDA) approval by BioSante, indicated for the
treatment of moderate-to-severe vasomotor symptoms associated with
menopause, and LibiGel� (transdermal testosterone gel) in Phase III
development for the treatment of female sexual dysfunction (FSD).
The current market in the U.S. for estrogen and testosterone
products is approximately $2.5 billion. The company also is
developing its calcium phosphate nanotechnology (CaP) for novel
vaccines, including hepatitis B, avian flu and biodefense vaccines
for toxins such as anthrax, as well as a system for delivering
drugs via alternative routes of administration. Additional
information is available online at: www.biosantepharma.com. This
news release contains forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995. The
statements regarding BioSante contained in this news release that
are not historical in nature, particularly those that utilize
terminology such as �may,� �will,� �should,� �likely,� �expects,�
�anticipates,� �estimates,� �believes,� �plans,� �hopes,� or
comparable terminology, are forward-looking statements.
Forward-looking statements are based on current expectations and
assumptions, and entail various risks and uncertainties that could
cause actual results to differ materially from those expressed in
such forward-looking statements. Important factors known to
BioSante that cause actual results to differ materially from those
expressed in such forward-looking statements are the difficulty of
developing pharmaceutical products, the success of clinical
testing, obtaining regulatory and other approvals and achieving
market acceptance, and other factors identified and discussed from
time to time in BioSante's filings with the Securities and Exchange
Commission, including those factors discussed in BioSante's most
recent Forms 10-K and 10-Q, which discussion also is incorporated
herein by reference. All forward-looking statements speak only as
of the date of this news release. BioSante undertakes no obligation
to update or revise any forward-looking statement, whether as a
result of new information, future events or otherwise.
Biosante Pharma (AMEX:BPA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Biosante Pharma (AMEX:BPA)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Biosante Pharmaceuticals (American Stock Exchange): 0 recent articles
More BioSante Pharmaceuticals, Inc. News Articles